Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
- PMID: 26316616
- PMCID: PMC4941099
- DOI: 10.1161/CIRCULATIONAHA.115.014281
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
Abstract
Background: Guidelines for heart failure (HF) recommend prescription of guideline-directed medical therapy before hospital discharge; some of these therapies are included in publicly reported performance measures. The burden of new medications for individual patients has not been described.
Methods and results: We used Get With The Guidelines-HF registry data from 2008 to 2013 to characterize prescribing, indications, and contraindications for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants. The difference between a patient's medication regimen at hospital admission and that recommended by HF quality measures at discharge was calculated. Among 158 922 patients from 271 hospitals with a primary discharge diagnosis of HF, initiation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was indicated in 18.1% of all patients (55.5% of those eligible at discharge were not receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at admission), β-blockers in 20.3% (50.5% of eligible), aldosterone antagonists in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligible), and anticoagulants in 18.0% (58.0% of eligible). Cumulatively, 0.4% of patients were eligible for 5 new medication groups, 4.1% for 4 new medication groups, 9.4% for 3 new medication groups, 10.1% for 2 new medication groups, and 22.7% for 1 new medication group; 15.0% were not eligible for new medications because of adequate prescribing at admission; and 38.4% were not eligible for any medications recommended by HF quality measures. Compared with newly indicated medications (mean, 1.45 ± 1.23), actual new prescriptions were lower (mean, 1.16 ± 1.00).
Conclusions: A quarter of patients hospitalized with HF need to start >1 medication to meet HF quality measures. Systems for addressing medication initiation and managing polypharmacy are central to HF transitional care.
Keywords: heart failure; medication adherence; medication therapy management; prescribing patterns, physician; quality of health care.
© 2015 American Heart Association, Inc.
Comment in
-
Rethinking the Focus of Heart Failure Quality Measures.Circulation. 2015 Oct 6;132(14):1307-10. doi: 10.1161/CIRCULATIONAHA.115.018692. Epub 2015 Aug 27. Circulation. 2015. PMID: 26316617 No abstract available.
Similar articles
-
Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.Arch Cardiovasc Dis. 2012 Jun-Jul;105(6-7):355-65. doi: 10.1016/j.acvd.2012.04.003. Epub 2012 Jun 28. Arch Cardiovasc Dis. 2012. PMID: 22800720
-
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.Lancet Glob Health. 2018 Sep;6(9):e1008-e1018. doi: 10.1016/S2214-109X(18)30306-1. Lancet Glob Health. 2018. PMID: 30103979
-
The impact of patient-specific quality-of-care report cards on guideline adherence in heart failure.Am Heart J. 2007 Dec;154(6):1174-83. doi: 10.1016/j.ahj.2007.08.007. Epub 2007 Oct 24. Am Heart J. 2007. PMID: 18035092 Clinical Trial.
-
A review of heart failure management in the elderly population.Am J Geriatr Pharmacother. 2009 Oct;7(5):233-49. doi: 10.1016/j.amjopharm.2009.10.001. Am J Geriatr Pharmacother. 2009. PMID: 19948300 Review.
-
Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure.Ann Pharmacother. 2006 Sep;40(9):1607-17. doi: 10.1345/aph.1H059. Epub 2006 Aug 8. Ann Pharmacother. 2006. PMID: 16896019 Review.
Cited by
-
Meta-Analysis of Medication Adherence Interventions Among Heart Failure Patients: The Lumpers Make Their Case.J Am Heart Assoc. 2016 Jun 17;5(6):e003827. doi: 10.1161/JAHA.116.003827. J Am Heart Assoc. 2016. PMID: 27317351 Free PMC article. No abstract available.
-
Real-world safety of neurohormonal antagonist initiation among older adults following a heart failure hospitalization.ESC Heart Fail. 2023 Jun;10(3):1623-1634. doi: 10.1002/ehf2.14317. Epub 2023 Feb 20. ESC Heart Fail. 2023. PMID: 36807850 Free PMC article.
-
Alignment of Doctors' Understanding of Treatment Burden Priorities and Chronic Heart Failure Patients' Experiences: A Nominal Group Technique Consultation.Patient Prefer Adherence. 2023 Jan 20;17:153-165. doi: 10.2147/PPA.S385911. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 36713974 Free PMC article.
-
Predictive Model for Heart Failure Readmission Using Nationwide Readmissions Database.Mayo Clin Proc Innov Qual Outcomes. 2022 May 17;6(3):228-238. doi: 10.1016/j.mayocpiqo.2022.04.002. eCollection 2022 Jun. Mayo Clin Proc Innov Qual Outcomes. 2022. PMID: 35601232 Free PMC article.
-
Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs.JAMA Cardiol. 2024 Nov 1;9(11):1029-1038. doi: 10.1001/jamacardio.2024.2969. JAMA Cardiol. 2024. PMID: 39320905
References
-
- Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O’Connor CM, Pieper K, Sun JL, Yancy C, Young JB. OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61–70. - PubMed
-
- Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184–192. - PMC - PubMed
-
- Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534–1541. - PubMed
-
- Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–327. - PubMed
-
- Bonow RO, Ganiats TG, Beam CT, Blake K, Casey DE, Jr, Goodlin SJ, Grady KL, Hundley RF, Jessup M, Lynn TE, Masoudi FA, Nilasena D, Pina IL, Rockswold PD, Sadwin LB, Sikkema JD, Sincak CA, Spertus J, Torcson PJ, Torres E, Williams MV, Wong JB. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation. 2012;125:2382–401. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous